Net Emergence of Substitutions at Position 28 on NS5A of Hepatitis C Virus Genotype 4 in Patients Failing Direct-Acting Antivirals by Next-Generation Sequencing

Hepatitis C virus (HCV) is a leading cause of morbidity and deaths worldwide. Despite the considerable reduction in number of HCV infections recently, there are still approximately 399  000 deaths each year largely due to hepatitis C-related liver diseases [1]. Remarkable advances have been made in treatment of HCV infection, notably with the introduction of direct-acting antivirals (DAAs). However, as a highly variable virus with many quasispecies, HCV can select in vitro and in vivo Resistance-Associated Substitutions (RASs) to antivirals in particular to anti-NS5A owing to their low genetic barrier [2].

Source: International Journal of Antimicrobial Agents - September 17, 2018 Category: Drugs & Pharmacology Authors: Thuy Nguyen, Sepideh Akhavan, Fabienne Caby, Luminita Bonyhay, Lucile Larrouy, Anne Gervais, Pascal Lebray, Thierry Poynard, Yvon Calmus, Anne Simon, Marc-Antoine Valantin, Vincent Calvez, Anne-Genevi ève Marcelin, Eve Todesco Tags: Short Communication Source Type: research